TTK protein kinase-derived HLA-A*2402-restricted peptide epitope (TTK-HLA-A*2402 epitope)

The TTK protein kinase-derived HLA-A*2402-restricted peptide epitope is a tumor-associated antigen (TAA) utilized in cancer immunotherapy, specifically for patients carrying the HLA-A*2402 allele. TTK, also known as Monopolar spindle 1 (MPS1) kinase, is a dual-specificity kinase essential for the spindle assembly checkpoint, ensuring accurate chromosome segregation during mitosis (PubMed: 18483464). While TTK expression is minimal in most normal adult tissues, it is significantly upregulated in various malignancies, including esophageal, breast, and lung cancers, making it an attractive target for the immune system (PubMed: 25113384). The specific epitope, often the 9-mer peptide SYRNEIAYL (known as TTK-719), is processed and presented on the cell surface by the HLA-A*2402 major histocompatibility complex (MHC) class I molecule. This peptide-HLA complex is recognized by the T-cell receptors (TCRs) of cytotoxic T lymphocytes (CTLs), which then mediate the targeted destruction of tumor cells. Therapeutic strategies focusing on this epitope include peptide-based vaccines, such as the OTS111 cocktail, and the development of TCR-engineered T-cell therapies (PubMed: 24651011). Clinical application requires screening for both the HLA-A*2402 genotype and TTK overexpression to ensure treatment efficacy.

Other names

TTK-719 peptideSYRNEIAYL peptideMPS1-derived HLA-A24 peptideTTK-derived HLA-A24 epitopeMonopolar spindle 1 kinase-derived HLA-A*2402-restricted peptide epitope

Induction of antigen-specific cytotoxic T lymphocytes (CTLs) that recognize and lyse tumor cells presenting the TTK-derived peptide in the context of HLA-A*2402.